These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26877611)

  • 21. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.
    Li L; Che L; Tharp KM; Park HM; Pilo MG; Cao D; Cigliano A; Latte G; Xu Z; Ribback S; Dombrowski F; Evert M; Gores GJ; Stahl A; Calvisi DF; Chen X
    Hepatology; 2016 Jun; 63(6):1900-13. PubMed ID: 26910791
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Matsumori T; Kodama Y; Takai A; Shiokawa M; Nishikawa Y; Matsumoto T; Takeda H; Marui S; Okada H; Hirano T; Kuwada T; Sogabe Y; Kakiuchi N; Tomono T; Mima A; Morita T; Ueda T; Tsuda M; Yamauchi Y; Kuriyama K; Sakuma Y; Ota Y; Maruno T; Uza N; Marusawa H; Kageyama R; Chiba T; Seno H
    Cancer Res; 2020 Dec; 80(23):5305-5316. PubMed ID: 33067264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of glycogen synthase 2 in intrahepatic cholangiocarcinoma prognosis assessment and its influence on the activity of cancer cells.
    A S; Wu H; Wang X; Wang X; Yang J; Xia L; Xia Y
    Bioengineered; 2021 Dec; 12(2):12167-12178. PubMed ID: 34783271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.
    Fujiwara H; Tateishi K; Kato H; Nakatsuka T; Yamamoto K; Tanaka Y; Ijichi H; Takahara N; Mizuno S; Kogure H; Matsubara S; Nakai Y; Koike K
    Cancer Sci; 2018 Nov; 109(11):3602-3610. PubMed ID: 30156013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo.
    Gu Y; Xiao L; Ming Y; Zheng Z; Li W
    Int J Oncol; 2016 May; 48(5):1868-76. PubMed ID: 26935808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma.
    Wang T; Drill E; Vakiani E; Pak LM; Boerner T; Askan G; Schvartzman JM; Simpson AL; Jarnagin WR; Sigel CS
    Hum Pathol; 2019 Sep; 91():19-25. PubMed ID: 31121195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma.
    Wang J; Zhang K; Wang J; Wu X; Liu X; Li B; Zhu Y; Yu Y; Cheng Q; Hu Z; Guo C; Hu S; Mu B; Tsai CH; Li J; Smith L; Yang L; Liu Q; Chu P; Chang V; Zhang B; Wu M; Jiang X; Yen Y
    Oncotarget; 2015 Aug; 6(22):18905-20. PubMed ID: 26056085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo.
    El Khatib M; Bozko P; Palagani V; Malek NP; Wilkens L; Plentz RR
    PLoS One; 2013; 8(10):e77433. PubMed ID: 24204826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
    Li H; Zhou ZQ; Yang ZR; Tong DN; Guan J; Shi BJ; Nie J; Ding XT; Li B; Zhou GW; Zhang ZY
    Hepatology; 2017 Jul; 66(1):136-151. PubMed ID: 28194813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
    Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
    Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma.
    Talabnin C; Janthavon P; Thongsom S; Suginta W; Talabnin K; Wongkham S
    Hum Pathol; 2016 Jun; 52():47-54. PubMed ID: 26980022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma.
    Kang YK; Kim WH; Lee HW; Lee HK; Kim YI
    Lab Invest; 1999 Apr; 79(4):477-83. PubMed ID: 10212000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
    Saha SK; Gordan JD; Kleinstiver BP; Vu P; Najem MS; Yeo JC; Shi L; Kato Y; Levin RS; Webber JT; Damon LJ; Egan RK; Greninger P; McDermott U; Garnett MJ; Jenkins RL; Rieger-Christ KM; Sullivan TB; Hezel AF; Liss AS; Mizukami Y; Goyal L; Ferrone CR; Zhu AX; Joung JK; Shokat KM; Benes CH; Bardeesy N
    Cancer Discov; 2016 Jul; 6(7):727-39. PubMed ID: 27231123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogene-Driven Induction of Orthotopic Cholangiocarcinoma in Mice.
    Plantureux C; Paillet J; Autret G; Pérez-Lanzón M; Kroemer G; Maiuri MC; Pol J
    Methods Mol Biol; 2024; 2769():99-108. PubMed ID: 38315392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma.
    Zhang X; Miao R; Liu T; Xiang X; Gu J; Jia Y; Li Z; Fu Y; He Y; Zhang Y; Zhang J; Qu K; Liu C
    Biomed Pharmacother; 2019 May; 113():108774. PubMed ID: 30889491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
    Wang H; Song X; Liao H; Wang P; Zhang Y; Che L; Zhang J; Zhou Y; Cigliano A; Ament C; Superville D; Ribback S; Reeves M; Pes GM; Liang B; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
    Hepatology; 2021 Jul; 74(1):248-263. PubMed ID: 33368437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
    Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
    J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
    Saha SK; Parachoniak CA; Ghanta KS; Fitamant J; Ross KN; Najem MS; Gurumurthy S; Akbay EA; Sia D; Cornella H; Miltiadous O; Walesky C; Deshpande V; Zhu AX; Hezel AF; Yen KE; Straley KS; Travins J; Popovici-Muller J; Gliser C; Ferrone CR; Apte U; Llovet JM; Wong KK; Ramaswamy S; Bardeesy N
    Nature; 2014 Sep; 513(7516):110-4. PubMed ID: 25043045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2.
    Nakanuma S; Tajima H; Okamoto K; Hayashi H; Nakagawara H; Onishi I; Takamura H; Kitagawa H; Fushida S; Tani T; Fujimura T; Kayahara M; Ohta T; Wakayama T; Iseki S; Harada S
    Int J Oncol; 2010 Apr; 36(4):793-800. PubMed ID: 20198321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features.
    Lee K; Song YS; Shin Y; Wen X; Kim Y; Cho NY; Bae JM; Kang GH
    Sci Rep; 2020 Sep; 10(1):15820. PubMed ID: 32978444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.